FDA informs Amazon of certain harmful sexual enhancement products for sale


July 29 (Reuters) – The United States Food and Drug Administration (FDA) notified Amazon.com Inc (AMZN.O) of the sale of sexual enhancement and weight loss products containing potentially harmful drug ingredients, in a letter to new boss Andy Jassy.

Amazon said it has removed the products in question and continues to work with the agency.

The FDA had previously warned consumers in December to avoid male enhancement and weight loss products sold through Amazon, eBay, and other retailers, citing hidden and unsafe drug ingredients.

Register now for FREE and unlimited access to reuters.com

Register now

In a letter As of July 26, the FDA said it had tested dozens of products purchased from December 2019 through February 2020 and found that they contained one or more of the drug ingredients sildenafil, tadalafil, and vardenafil.

None of these ingredients have been named in product labeling, the health regulator said.

Sildenafil, Tadalafil, and Vardenafil are active ingredients in FDA-approved prescription drugs, Viagra, Cialis, and Levitra, which are used to treat erectile dysfunction.

These ingredients could interact with certain prescription drugs and lower blood pressure to dangerous levels, the FDA said.

“We continue to find potentially dangerous products available for purchase and urge stores, websites and online marketplaces, including Amazon, to do more to protect consumers by not selling or facilitating the sale of Potentially dangerous and illegal FDA-regulated products, ”the health regulator said on Twitter Thursday.

In one case, the FDA said it purchased a product from Amazon’s website that the company previously said it restricted, adding that it was concerned that the e-commerce site’s filters were inadequate.

The FDA has asked Amazon to submit a written response within 15 business days on the steps it has taken to address these violations.

Register now for FREE and unlimited access to reuters.com

Register now

Reporting by Nivedita Balu, Manas Mishra and Tiyashi Datta in Bengaluru; Editing by Krishna Chandra Eluri

Our standards: Thomson Reuters Trust Principles.


Comments are closed.